Healthcare
Sempli Farma® revolutionizes the way drugs are taken through a repackaging service in Custom Unit Doses in pharmacies.
Revenues €1.23 mln in 2022 (+965% vs 2021) and positive EBITDA of 13.1%
More than 2,500 patients service users through 61 partner pharmacies and 26 RSAs
More than 50 percent of pharmacies providing the automated service in Italy are Sempli Farma® branded
High potential for market growth: 8.8 mln Italians taking more than 5 tablets a day
TAX Bonus
Innov SME
SIM
LP
Sempli Farma®, a brand of Remedio Srl, proposes that pharmacies become repackaging centers for sachets ("Personalized Unit Doses") of oral solid drug therapies.
The sachets make it easier and safer for patients to take the right drug, with the right dose, at the right time, thus increasing adherence to therapies, the lack of which touches 50 percent of the 8.8 million poly-treated people in Italy (those who take more than 5 tablets a day), causing morbidity and avoidable costs for the SSN of about 19 billion a year (emergency room accesses, hospitalizations, treatments).
By investing you will become a partner in one of the first movers of a booming market. Sempli Farma®'s service already has 18 repackaging center pharmacies and 43 satellite pharmacies, with more than 2,500 patients served. Revenues for 2022 were € 1.23 mln, with EBITDA 13.1%.
The company's strategic design touches on three points:
Specifically, Sempli Farma® provides pharmacies with a sophisticated hardware & software system, which repackages into sachets the medications (tablets or tablets) that the individual patient needs to take at a certain time of the day. The sachets are dispensed either with a simple dispenser, in which the string of sachets (roll) is ordered chronologically, or with a "smart dispenser, " which dispenses the right sachet, already cut, at the predetermined time and reminds the patient, with beeps and lights, that it is time to take it.
Sempli Farma® brings technological, organizational, marketing & sales know-how to pharmacies. It sells repackaging technologies, access to the platform that communicates with prescription and medication management systems (recurrent fees from maintenance, support, consumables and software use licenses). It also receives patient/day fees for Site Management service (which maximizes in-house labor productivity to reduce unit production costs) and Business Development service (marketing activities and patient research for the pharmacy). Other recurrent revenues come from the development of the therapeutic adherence marketplace (platform access and online sales of the Sempli Farma® repackaging service and other related goods and services).
Tax benefits of 30% apply on Sempli Farma.
Sempli Farma reserves the right of "liquidation preference" for all investors participating in the campaign, who will therefore be reimbursed first in the event of an exit than the company's other shareholders (according to the order of preference indicated in the bylaws). All conditions are published in the bylaws found in the Documents section.
On the campaign is available the optional Rubrication free of charge for the Investor as the costs are borne by Sempli Farma.
Sempli Farma
Healthcare
Total funding
344.314 €
Goal min 150k €
Goal max 588,57k €
114 investors
245% Goal min
Minimum order
498,52 €
Pre-Money
7,50Mln €
Warnings pursuant to Article 19(2)
crowdfunding services provided by Mamacrowd are not covered by the Deposit Guarantee Scheme established in accordance with Directive 2014/49/EU*; securities and instruments eligible for crowdfunding purposes that can be acquired through this crowdfunding platform are not covered by the Investor Compensation Scheme established in accordance with Directive 97/9/EC**.
* Directive 2014/49/EU of the European Parliament and of the Council on Deposit Guarantee Schemes.
** Directive 97/9/EC of the European Parliament and of the Council on investor-compensation schemes.
© 2024 Mamacrowd Srl a company of Azimut Group - VAT number IT07464370969 - Via Timavo 34, 20124 MI - SC € 95.417,54 fully paid up - Crowdfunding service provider authorised by resolution No. 22876 of 08/11/2023
Italiano
English
Italiano
English
Let us get to know you better
Mamacrowd and partners operate globally and can, upon acquiring your consent through the "Accept all", "Accept only necessary" or "Set preferences" commands, use cookies for statistical, advertising and also profiling purposes, own or third-party, to modulate the provision of the service in a personalized way and in line with your preferences.
In case of refusal we will only use the necessary cookies. For more information, read our Cookies Policy